Latest Ratios: P/E Ratio 30.1x · EV/EBITDA 41.7x · ROE 34.1%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $550M | $478M | $308M | $212M | $210M | $254M | $508M | $239M | $106M | $284M | $25M |
| Enterprise Value | $599M | $527M | $325M | $183M | $152M | $161M | $445M | $215M | $83M | $255M | $43M |
| P/E Ratio → | 30.06 | 18.21 | — | — | — | 32.08 | 56.58 | — | — | 48.77 | — |
| P/S Ratio | 10.55 | 9.17 | 10.79 | 44.60 | 34.84 | 6.66 | 17.28 | 13.02 | 19.99 | 5.39 | 4.57 |
| P/B Ratio | 7.59 | 4.60 | 3.75 | 2.39 | 1.69 | 1.79 | 5.87 | 5.44 | 5.64 | 49.10 | — |
| P/FCF | 191.72 | 166.54 | — | — | — | — | 57.15 | — | — | 106.08 | — |
| P/OCF | 191.72 | 166.54 | — | — | — | 11.21 | 50.30 | — | — | 105.77 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.10 | 11.41 | 38.54 | 25.25 | 4.22 | 15.13 | 11.73 | 15.59 | 4.84 | 7.70 |
| EV / EBITDA | 41.73 | 36.69 | — | — | — | 9.10 | 35.32 | — | — | 14.72 | — |
| EV / EBIT | 52.62 | 11.75 | — | — | — | 9.85 | 32.60 | — | — | 14.59 | — |
| EV / FCF | — | 183.49 | — | — | — | — | 50.06 | — | — | 95.29 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.3% | 94.3% | 99.3% | 97.0% | 95.5% | 99.6% | 99.4% | 93.2% | 68.3% | 85.1% | 74.8% |
| Operating Margin | 21.8% | 21.8% | -140.3% | -879.5% | -288.9% | 45.9% | 42.3% | -21.1% | -318.1% | 32.3% | -1106.4% |
| Net Profit Margin | 60.8% | 60.8% | -48.5% | -858.2% | -283.8% | 41.4% | 45.3% | -10.8% | -251.8% | 27.7% | -962.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 34.1% | 34.1% | -16.2% | -38.4% | -12.9% | 13.8% | 20.4% | -6.3% | -108.6% | 252.3% | — |
| ROA | 12.8% | 12.8% | -6.1% | -21.8% | -11.1% | 10.8% | 12.0% | -2.5% | -24.5% | 39.7% | -103.4% |
| ROIC | 6.8% | 6.8% | -37.6% | -49.8% | -22.7% | 36.4% | 42.7% | -37.3% | — | — | — |
| ROCE | 5.2% | 5.2% | -19.4% | -24.0% | -12.1% | 13.2% | 12.4% | -5.4% | -35.3% | 101.1% | -257.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.27 | 1.27 | 1.46 | 1.40 | 0.00 | 0.00 | 0.25 | 0.75 | 1.20 | 2.52 | — |
| Debt / EBITDA | 9.16 | 9.16 | — | — | — | 0.01 | 1.69 | — | — | 0.84 | — |
| Net Debt / Equity | — | 0.47 | 0.21 | -0.33 | -0.47 | -0.66 | -0.73 | -0.54 | -1.24 | -4.99 | — |
| Net Debt / EBITDA | 3.39 | 3.39 | — | — | — | -5.26 | -5.00 | — | — | -1.67 | — |
| Debt / FCF | — | 16.94 | — | — | — | — | -7.09 | — | — | -10.79 | — |
| Interest Coverage | 3.44 | 3.44 | -0.41 | -41.24 | — | 35.47 | 7.40 | -2.02 | -13.62 | 14.13 | -12.57 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.37 | 3.37 | 5.15 | 8.68 | 8.98 | 7.48 | 7.16 | 6.76 | 8.35 | 5.95 | 0.84 |
| Quick Ratio | 3.37 | 3.37 | 5.15 | 8.68 | 8.98 | 7.48 | 7.03 | 6.76 | 8.35 | 5.95 | 0.84 |
| Cash Ratio | 2.39 | 2.39 | 4.32 | 7.87 | 8.53 | 7.26 | 6.85 | 6.39 | 8.03 | 5.86 | 0.79 |
| Asset Turnover | — | 0.19 | 0.13 | 0.02 | 0.04 | 0.23 | 0.23 | 0.19 | 0.08 | 1.17 | 0.19 |
| Inventory Turnover | — | — | — | — | — | — | 0.11 | — | — | — | — |
| Days Sales Outstanding | — | 34.27 | 218.01 | 1167.49 | 143.35 | 2.00 | 22.22 | 58.28 | 101.12 | 2.75 | 37.13 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.7% | 1.1% | 1.8% | 2.6% | 2.6% | 1.4% | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.3% | 5.5% | — | — | — | 3.1% | 1.8% | — | — | 2.1% | — |
| FCF Yield | 0.5% | 0.6% | — | — | — | — | 1.7% | — | — | 0.9% | — |
| Buyback Yield | 2.9% | 3.4% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 3.6% | 4.5% | 1.8% | 2.6% | 2.6% | 1.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $18M | $12M | $11M | $11M | $12M | $12M | $9M | $8M | $8M | $6M |
Binary Milestone Revenue Volatility
According to current market data, XOMA trades at a P/S multiple of 10.14 and a forward P/E of 53.68, suggesting that investors are pricing the company as a high-growth biotech proxy rather than a stable, yield-generating financial vehicle compared to peers like Royalty Pharma.
The elevated valuation multiples appear to bake in significant expectations for future milestone successes across the 70-asset portfolio. Investors should monitor whether this premium is sustainable, as the current P/FCF of 184.12 implies that the market is heavily discounting near-term cash flow volatility in favor of long-term clinical optionality.
Based on reported figures, XOMA's ROIC has fluctuated significantly, ranging from a low of -22.6% in 2023Q4 to a peak of 4.3% in 2025Q1, which indicates that the company is still struggling to consistently compound returns on its invested capital within the biotech royalty space.
The inconsistency in ROIC suggests that the timing of asset acquisitions and the subsequent clinical outcomes are not yet generating a stable return profile. This volatility warrants further investigation into whether the current portfolio mix can achieve the scale necessary to drive sustained, positive returns on invested capital over the long term.
As reported in recent financial statements, XOMA's asset turnover ratio remains exceptionally low, consistently hovering near 0.05, which reflects the inherent nature of holding long-duration, non-manufacturing intangible assets that do not generate rapid, high-velocity revenue streams compared to traditional industrial or service-based business models.
The low turnover is a structural reality of the royalty aggregation model rather than an operational failure. However, the extended DSO figures, which reached 727 in 2025Q4, suggest that the company faces significant friction in the timing of royalty collections, which may complicate short-term liquidity management.
Based on the latest quarterly data, XOMA maintains a debt-to-equity ratio of 1.10, which, when viewed alongside a current ratio of 3.59, suggests that the company is operating with a healthy balance sheet that provides ample room for future portfolio expansion without immediate refinancing risk.
The company's ability to maintain this leverage profile while avoiding excessive interest burdens appears to be a key strength. Investors should monitor whether management chooses to utilize this capacity to acquire additional assets, as the current low interest coverage in certain quarters suggests that debt service remains sensitive to revenue lumpiness.
The P/E ratio is frequently misapplied to XOMA, as reported in financial analysis, because it fails to account for the significant non-cash amortization of intangible assets and the lumpy, non-recurring nature of milestone payments that distort the company's true underlying earning power.
Investors should instead focus on Adjusted EBITDA or cash receipts to better gauge the sustainability of the business model. Relying on GAAP P/E ratios likely obscures the actual cash-generating capacity of the royalty portfolio and may lead to an inaccurate assessment of the company's valuation relative to its peers.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XOMA stock.
XOMA Royalty Corp.'s current P/E ratio is 30.1x. The historical average is 41.8x. This places it at the 20th percentile of its historical range.
XOMA Royalty Corp.'s current EV/EBITDA is 41.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.3x.
XOMA Royalty Corp.'s return on equity (ROE) is 34.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -89.1%.
Based on historical data, XOMA Royalty Corp. is trading at a P/E of 30.1x. This is at the 20th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
XOMA Royalty Corp.'s current dividend yield is 0.69%.
XOMA Royalty Corp. has 94.3% gross margin and 21.8% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
XOMA Royalty Corp.'s Debt/EBITDA ratio is 9.2x, indicating high leverage. A ratio above 4x may signal elevated financial risk.